People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Diffusion Pharmaceuticals Llc | — | Pharmaceuticals | Series A | $23.7M | $74.4M | 2009 |
Matthew Hantzmon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Hantzmon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew W. Hantzmon | 1 | 3 |
| Thomas E. Byrne | 1 | 2 |
| John L. Gainer | 1 | 2 |
| Mark T. GIles | 1 | 2 |
| Robert W. Adams | 1 | 2 |
| Ben L. Shealy | 1 | 2 |
| David Kalergis | 1 | 2 |
| David R. Jones | 1 | 2 |
| David G. Kalergis | 1 | 2 |
| Alan R. Levin | 1 | 1 |
| Kim L. Whitten | 1 | 1 |
| Matthew L. Hantzmon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.